ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells
HY Jia, JX Wu, XF Zhu, JM Chen, SP Yang, HJ Yan… - Leukemia research, 2009 - Elsevier
ZD6474 is an orally available, small-molecule tyrosine kinase inhibitor. This study explores
the effect of ZD6474 on imatinib-resistant K562 cell lines, which show markedly increased
SRC family kinases (SFKs) activity. ZD6474 induces growth arrest and apoptosis of imatinib-
resistant and parental K562 cells, as well as inhibition of Src activity and its downstream
effectors, the anti-apoptotic Bcl-2 family. ZD6474 treatment also inhibits the activity of STAT3
and reactivation of its activity results in suppression of the anti-tumor effects of SFKs …
the effect of ZD6474 on imatinib-resistant K562 cell lines, which show markedly increased
SRC family kinases (SFKs) activity. ZD6474 induces growth arrest and apoptosis of imatinib-
resistant and parental K562 cells, as well as inhibition of Src activity and its downstream
effectors, the anti-apoptotic Bcl-2 family. ZD6474 treatment also inhibits the activity of STAT3
and reactivation of its activity results in suppression of the anti-tumor effects of SFKs …